Dade joins HF (heart failure) blood testing market in the US:
This article was originally published in Clinica
Dade Behring has joined the growing rank of companies to have entered the emerging heart failure (HF) blood test market in the US. The Deerfield, Illinois firm has received FDA clearance to sell its cardiac marker assay NT-proBNP (N-terminal pro brain natriuretic peptide), which will be run on the company's Dimension instruments. Product shipments are anticipated to begin in the fourth quarter of this year. This is one quarter later than the original anticipated launch date due to antibody supply timing, the company said. Other firms to have gained approval to sell BNP-based HF tests are Biosite, Bayer Diagnostics, Roche Diagnostics, Axis-Shield and Abbott Laboratories.